Endoret®(prgf®) technology has the greatest product versatility on the market, presenting four therapeutic formulations based on the patient's blood and adapted to the clinical needs of each case. We can work with Endoret®(prgf®) in the form of supernatant liquid, a clot or an autologous fibrin membrane.
As a result of this versatility, the research and development team at BTI has obtained a publication with a high level of impact, explaining the versatility of formulations obtained with Endoret®(prgf®) technology..
What sets us apart
Today there is a growing interest in Platelet-Rich Plasmas (PRP’s), but Endoret®(prgf®) is easily distinguished from other PRP’s thanks to its versatility, which makes it possible to obtain up to four different formulations from the patient's own blood with therapeutic potential depending on the level of coagulation and activation of the samples.
In addition to its versatility, there are several other factors that set Endoret®(prgf®) apart from other PRP’s:
- It uses an anticoagulant that does not damage the platelets
- The activator of Endoret®(prgf®) is calcium chloride
- It does not contain leucocytes
- Just one centrifugation
- Simple protocol
- 100% autologous, biocompatible and safe.
Intended for international use only. Indications for use of products and/or therapies contained herein may not be cleared /approved for use by the following Health international agencies: US Food & Drug Administration, Health Canada or Japanese Health Ministry. To access the specific information of your market, use the country selector located on the top menu of this page.